Skip to main content
. 2020 Apr 8;10:6058. doi: 10.1038/s41598-020-62961-5

Figure 3.

Figure 3

Stratified analysis of progression-free and overall survival by variables. Kaplan–Meier curve of (a) PFS and (b) OS in patients who were previously treated with or without anti-VEGF therapies, (c) PFS and (d) OS in patients with different NLR levels, (e) PFS and (f) OS in patients with or without CA19-9 decrease, and (g) PFS and (h) OS in patients with or without HFS. PFS, progression-free survival; OS, overall survival; VEGF, vascular endothelial growth factor; NLR, neutrophil/lymphocyte ratio; carbohydrate antigen 19-9, CA19-9; HFS, hand-foot syndrome; HR, hazard ratios; CI, confidence interval.